Prot #BGB-11417-203: An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia

Project: Research project

Project Details

StatusActive
Effective start/end date9/27/249/27/27

Funding

  • BeiGene USA, Inc. (Prot #BGB-11417-203)